TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03117699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New device for seated-standing passages
Description: Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New device for seated-standing passages
Description: Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair
Study: NCT03607461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Home Health users will have received traditional home health physical therapy and skilled nursing services.
Study: NCT01713257

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoenhancing diet
Description: Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric, isonitrogenous diet
Description: Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
Study: NCT02791477

Intervention type: DEVICE
Group type: OTHER
Intervention: Attune FB PS knee arthroplasty
Study: NCT03631394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beetroot and anthocyanin
Description: Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: beetroot and placebo
Description: Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
Study: NCT02168660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, liquid formulation, 5000 IU/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, liquid formulation, 5000 IU/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, liquid formulation, 5000 IU/mL.
Study: NCT00852761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olux-E Foam
Description: Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobex lotion
Description: Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
Study: NCT00417391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RR110 (Tamibarotene)
Description: 1 mg RR110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RR110 (Tamibarotene)
Description: 4 mg RR110
Study: NCT00169338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: internal pallidal deep brain stimulation
Study: NCT03885674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Call Reminder Condition
Description: Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Text Message Reminder Condition
Description: Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
Study: NCT02462889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Description: Intravitreal aflibercept injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham injection
Study: NCT03973632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028 Tablets
Description: 200mg of SH-1028 Tablets, orally once every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028 Tablets
Description: 200mg of SH-1028 Tablets, orally once every cycle.
Study: NCT02033291

Intervention type: PROCEDURE
Intervention: Dynamic contrast enhanced Brain MRI
Description: DCE-MRI is used to quantify the BBB permeability

Intervention type: PROCEDURE
Intervention: Dynamic contrast enhanced Brain MRI
Description: DCE-MRI is used to quantify the BBB permeability
Study: NCT02814812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Study: NCT01902654

Intervention type: OTHER
Intervention: Cardiovascular risk factors diagnoses collection.
Description: We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.

Intervention type: OTHER
Intervention: Cardiovascular risk factors diagnoses collection.
Description: We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.

Intervention type: OTHER
Intervention: Cardiovascular risk factors diagnoses collection.
Description: We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.

Intervention type: OTHER
Intervention: History of cardiovascular disease
Description: In all patient we collect the history of cardiovascular disease.

Intervention type: OTHER
Intervention: History of cardiovascular disease
Description: In all patient we collect the history of cardiovascular disease.

Intervention type: OTHER
Intervention: History of cardiovascular disease
Description: In all patient we collect the history of cardiovascular disease.

Intervention type: OTHER
Intervention: Cardiovascular risk factors association
Description: We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.

Intervention type: OTHER
Intervention: Cardiovascular risk factors association
Description: We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
Study: NCT01822431

Intervention type: RADIATION
Intervention: metaiodobenzylguanidine scintigraphy
Study: NCT01902654

Intervention type: OTHER
Intervention: Cardiovascular risk factors association
Description: We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
Study: NCT00443365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair
Description: mitral valve annuloplasty
Study: NCT03861234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection
Study: NCT02408718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assistive Device Training
Description: Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
Study: NCT01051531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
Study: NCT00780143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin plus Cytarabine
Description: Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
Study: NCT00725192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 12 sessions of Cognitive Processing Therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 12 sessions of Cognitive Processing Therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
Study: NCT04410848

Intervention type: OTHER
Intervention: To determine the diagnostic of Choledocholithiasis with symbolic regression model
Description: To determine the diagnostic of Choledocholithiasis with symbolic regression model
Study: NCT03076060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Diet
Description: Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD.
Study: NCT03560960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide challenge test
Description: Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide challenge test
Description: Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide challenge test
Description: Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
Study: NCT00911196

Intervention type: OTHER
Intervention: Retrospective analysis of already archived samples
Description: Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
Study: NCT03088930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
Study: NCT03296748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans-obturator tape inside-out usingsoft tapes.
Description: trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans-obturator tape inside-out usingsoft tapes.
Description: trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior colporraphy
Study: NCT04743336

Intervention type: OTHER
Intervention: Measuring pocket depth
Description: Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar

Intervention type: OTHER
Intervention: Measuring pocket depth
Description: Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar

Intervention type: OTHER
Intervention: Measuring pocket depth
Description: Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
Study: NCT03515733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: PF-04995274 tablets
Study: NCT03861234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection
Study: NCT02807155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Empowerment Program
Description: Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
Study: NCT05914896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HighOsmo
Description: This group received a priming solution with high osmolality
Study: NCT04036955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INFOSA-DEM
Description: Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
Study: NCT01920191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA 950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly ICLC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunomonitoring
Description: Blood samples, DTH analysis
Study: NCT01404585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-817399
Description: Tablets, Oral, 200 mg, twice daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-817399
Description: Tablets, Oral, 400mg, twice daily, 12 weeks
Study: NCT02807155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)
Description: Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Transition Empowement Program Access
Description: Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
Study: NCT01784744

Intervention type: OTHER
Intervention: Hydroworx Pool at 98 degrees Fahrenheit

Intervention type: OTHER
Intervention: Hydroworx Pool at 102 degrees Fahrenheit

Intervention type: OTHER
Intervention: Hydroworx Pool at 102 degrees Fahrenheit
Study: NCT02099123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Atorvastatin)
Description: Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
Study: NCT02786446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel,
Description: 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel and Naproxen Sodium
Description: Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Study: NCT04121377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected.
Study: NCT03809416

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lasers
Description: Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lasers
Description: Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelets Rich Plasma
Description: Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Lasers plus Normal Saline Solution
Description: Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
Study: NCT02224105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 BS
Study: NCT05815940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: a mobile application was developed that can be used by children with urinary incontinence and their parents.